Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients

Ayşegül Uğur Kurtoğllu; Belkls Koçtekin; Erdal Kurtoğlu; Mustafa Yildiz; Selen Bozkurt

doi:10.5114/ceji.2017.67321

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

1/2017
vol. 42

Send email

Copy url:

abstract:

Clinical immunology

Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients

Ayşegül Uğur Kurtoğllu

,

Belkls Koçtekin

,

Erdal Kurtoğlu

,

Mustafa Yildiz

,

Selen Bozkurt

(Cent Eur J Immunol 2017; 42 (1): 78-84)

DOI: https://doi.org/10.5114/ceji.2017.67321

Online publish date: 2017/05/08

View full text Get citation

PlumX metrics:

Aim of the study: β-thalassaemia (β-Thal) is considered a severe, progressive haemolytic anaemia, which needs regular blood transfusions for life expectancy. Complement-mediated erythrocyte destruction can cause both intravascular and extravascular haemolysis. Complement regulatory proteins protect cells from such effects of the complement system. We aimed to perform quantitative analysis of membrane-bound complement regulators, CD55 (decay accelerating factor – DAF), CD35 (complement receptor type 1 – CR1), and CD59 (membrane attack complex inhibitory factor – MACIF) on peripheral red blood cells by flow cytometry.

Material and methods: The present study was carried out on 47 β-thalassemia major (β-TM) patients, 20 β-thalassaemia intermedia (β-TI) patients, and 17 healthy volunteers as control subjects.

Results: CD55 levels of β-TM patients (58.64 ±17.06%) were significantly decreased compared to β-TI patients (83.34 ±13.82%) and healthy controls (88.57 ±11.69%) (p < 0.01). CD59 levels of β-TM patients were not significantly different than β-TI patients and controls, but CD35 levels were significantly lower in the β-TM patients (3.56 ±4.87%) and β-TI patients (12.48 ±9.19%) than in the control group (39.98 ±15.01%) (p < 0.01).

Conclusions: Low levels of CD55 and CD35 in thalassaemia major patients indicates a role for them in the aetiopathogenesis of haemolysis in this disease, and also this defect in a complement system may be responsible for the chronic complications seen in these patients.

keywords:

Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients

Ayşegül Uğur Kurtoğllu , Belkls Koçtekin , Erdal Kurtoğlu , Mustafa Yildiz , Selen Bozkurt

CD55, CD59, CD35, β-thalassemia

Ayşegül Uğur Kurtoğllu

,

Belkls Koçtekin

,

Erdal Kurtoğlu

,

Mustafa Yildiz

,

Selen Bozkurt